A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

March 01, 2018
https://clinicaltrials.gov/ct2/show/NCT03442764
Cardiac, Cardiology Heart Failure, Congestive Heart Failure, Heart
Principal Investigator: Karthikeyan Ananthasubramaniam, MD
heart, cardiomyopathy, HOCM, hypertrophic obstructive cardiomyopathy, heart disease 
Accepting Participants